Table 1.
Patient Demographics, Histopathologic Features, and Iodine Metabolizing Gene Expression.
| Total (N=47) | BRAF V600E (N=24) | BRAFwt (N=23) | P-value* | |
|---|---|---|---|---|
|
| ||||
| PATIENT DEMOGRAPHICS | ||||
|
| ||||
| Age (mean±SD) | 44.2±13.9 | 46.0±15.2 | 42.2±12.5 | 0.35 |
| Gender | ||||
| Male (N=12) | 12 (25.5%) | 7 (58.3%) | 5 (41.7%) | 0.74 |
| Female (N=35) | 35 (74.5%) | 17 (48.6%) | 18 (53.3%) | |
|
| ||||
| HISTOPATHOLOGIC FEATURES | ||||
|
| ||||
| Tumor size in cm [median (range)] | 1.5 (0.7–8.0) | 1.9 (0.8–8.0) | 1.2 (0.7–4.5) | 0.12 |
| Histologic Subtypes | ||||
| Papillary carcinoma (PTC) | 24 (51.1%) | 13 (54.2%) | 11 (45.8%) | 0.77 |
| Follicular variant of PTC | 11 (23.4%) | 2 (18.2%) | 9 (81.8%) | 0.02 |
| Tall cell variant of PTC | 6 (12.8%) | 5 (83.3%) | 1 (16.7%) | 0.19 |
| Follicular carcinoma | 2 (4.3%) | 0 (0%) | 2 (100%) | 0.23 |
| Poorly differentiated | 4 (8.5%) | 4 (100%) | 0 (0%) | 0.11 |
| Extrathyroidal extension | 25 (53.2%) | 17 (68%) | 8 (32%) | 0.02 |
| Lymphovascular invasion | 11 (23.4%) | 7 (63.4%) | 4 (36.4%) | 0.49 |
| Multifocality | 18 (38.3%) | 9 (50.0%) | 9 (50.0%) | 1.00 |
| Lymph node metastases | 20 (42.6%) | 11 (55.0%) | 9 (45.0%) | 0.77 |
|
| ||||
| IODINE METABOLIZING GENE EXPRESSION** | ||||
|
| ||||
| NIS | 0.53 ± 0.35 | 0.27 ± 0.03 | 0.78 ± 0.09 | <0.01 |
| TSHr | 0.62 ± 0.05 | 0.42 ± 0.09 | 0.71 ± 0.02 | <0.01 |
• p-values were derived using student’s t-test (age and gene expression), Wilcoxon rank-sum test (tumor size), and Fisher’s exact chi-squared (all other variables).
**
Gene expression given as ΔΔ CT±SD.